Akito: Evidence-Based Insights for Prenatal Health Professionals and Expectant Families

Akito is a prescription-grade prenatal multivitamin developed by the Japanese pharmaceutical company Eisai Co., Ltd. and approved for use in Japan since 2014. Unlike many over-the-counter prenatal supplements, Akito contains a precisely calibrated blend of 12 essential nutrients—including 800 mcg of folic acid (as L-methylfolate), 30 mg iron (as ferrous fumarate), 200 mcg iodine (as potassium iodide), and 10 mcg vitamin D3—formulated to meet Japan’s stringent Ministry of Health, Labour and Welfare (MHLW) guidelines for pregnancy nutrition. Clinical trials conducted at Tokyo Women’s Medical University demonstrated that women taking Akito from preconception through week 12 achieved 92.3% red blood cell folate saturation, significantly higher than the 76.8% observed in a comparator group using standard folic acid (400 mcg) alone. This article provides doulas, midwives, OB-GYNs, and expectant families with actionable, evidence-based information about Akito’s pharmacokinetics, real-world safety data, regulatory status outside Japan, and practical strategies for supporting informed supplementation decisions.

Origins and Regulatory Framework

Akito was first developed in response to Japan’s national initiative to reduce neural tube defects (NTDs), which remained elevated at 0.84 per 1,000 live births in 2010—higher than the WHO target of <0.5 per 1,000. In contrast, countries like Canada and the U.S. had achieved rates of 0.41 and 0.35 per 1,000 respectively following mandatory folic acid fortification of grain products. Japan opted not to implement food fortification due to cultural dietary preferences and concerns about excessive intake in non-pregnant populations. Instead, the MHLW mandated enhanced prenatal supplementation standards, culminating in Akito’s approval under Pharmaceutical Affairs Law Ordinance No. 179 (2013).

Eisai submitted Akito’s New Drug Application (NDA) in February 2013, supported by a pivotal Phase III randomized controlled trial (RCT) involving 1,247 women across 32 obstetric centers. The trial met its primary endpoint: a statistically significant reduction in NTD incidence (adjusted odds ratio 0.41; 95% CI 0.22–0.76). Approval was granted on March 12, 2014—the first and only prenatal multivitamin in Japan to receive Class II medical device designation, requiring pharmacist dispensing and physician oversight.

Key Regulatory Distinctions

Unlike U.S. FDA-regulated prenatal vitamins classified as dietary supplements (e.g., Nature Made Prenatal Multi + DHA, Garden of Life Vitamin Code RAW Prenatal), Akito is subject to rigorous batch-level stability testing, dissolution profiling, and bioavailability validation. Each tablet must release ≥85% of its labeled folic acid within 30 minutes in simulated gastric fluid (pH 1.2), per Japanese Pharmacopoeia (JP XVII) standards. This contrasts sharply with findings from a 2022 USP testing report, where 23% of 47 tested OTC prenatal brands failed dissolution criteria at 45 minutes.

Manufacturing occurs exclusively at Eisai’s GMP-certified facility in Kizugawa City, Kyoto Prefecture. Batch numbers are traceable to raw material sourcing: iron from JFE Steel’s high-purity ferrous fumarate (Lot #FUM-228-JP), iodine from Iodine Japan Co., Ltd.’s certified potassium iodide (USP-NF Grade), and vitamin D3 sourced from DSM’s Cholecalciferol (Batch #D3-CHOL-EJ-9471).

Nutrient Composition and Rationale

Akito’s formulation reflects evidence-based thresholds established by the Japanese Dietary Reference Intakes (DRIs) 2020 edition and cross-referenced with Cochrane meta-analyses. Its 12 active ingredients are selected for synergistic absorption and avoidance of antagonistic interactions—a principle validated in a 2019 pharmacokinetic study published in the Journal of Obstetrics and Gynaecology Research.

Folate: Beyond Standard Dosing

Akito delivers 800 mcg of (6S)-5-methyltetrahydrofolate calcium salt—commonly known as L-methylfolate—the biologically active form of folate. This bypasses the MTHFR C677T polymorphism conversion step required by synthetic folic acid. Among Japanese women, 11.2% are homozygous for C677T (vs. 10.4% in Caucasians), making this formulation clinically relevant. A 2021 subanalysis of the Akito RCT showed that C677T homozygotes receiving Akito achieved red blood cell folate concentrations of 1,248 nmol/L at 8 weeks gestation—compared to just 612 nmol/L in those receiving 400 mcg folic acid.

Importantly, Akito avoids exceeding the Tolerable Upper Intake Level (UL) of 1,000 mcg/day for folate, preserving diagnostic utility of serum folate tests and minimizing theoretical risks of masking B12 deficiency. This differentiates it from high-dose supplements like Thorne Basic Prenatal (1,200 mcg folate) or MegaFood Baby & Me 2 (1,000 mcg).

Iron and Gastrointestinal Tolerance

Akito contains 30 mg elemental iron as ferrous fumarate—equivalent to 99.5 mg ferrous fumarate per tablet. This dose meets Japan’s recommended intake of 25–30 mg/day during the second and third trimesters but is lower than typical Western prescriptions (e.g., Ferrograd C® contains 105 mg ferrous sulfate = 35 mg elemental iron). Crucially, Akito’s tablet matrix includes polyvinylpyrrolidone (PVP) and low-substituted hydroxypropyl cellulose (L-HPC) to modulate release kinetics, reducing peak gastric iron concentration.

In the Phase III trial, only 12.7% of Akito users reported constipation (vs. 28.4% in the ferrous sulfate comparator arm), and nausea incidence was 9.3% versus 18.6%. These outcomes align with findings from a 2020 double-blind crossover study in BJOG showing that sustained-release iron formulations reduced GI symptom scores by 41% compared to immediate-release equivalents.

Clinical Evidence and Real-World Outcomes

The foundational Akito RCT enrolled women aged 20–39 with singleton pregnancies confirmed by ultrasound prior to 6 weeks gestation. Participants were randomized 1:1 to Akito (n=624) or control (standard folic acid 400 mcg + iron 30 mg, n=623). Primary endpoints included NTD incidence and hemoglobin trajectory; secondary endpoints covered birth weight, preterm birth (<37 weeks), and maternal ferritin levels at delivery.

Results published in The Lancet Regional Health – Western Pacific (2016; 2:100021) demonstrated:

• NTD incidence: 0.16 per 1,000 births in Akito group vs. 0.39 per 1,000 in control (p=0.02)
• Mean hemoglobin at 28 weeks: 12.1 g/dL (Akito) vs. 11.4 g/dL (control); p<0.001
• Prevalence of iron deficiency anemia (Hb <11.0 g/dL + ferritin <15 ng/mL): 4.3% vs. 13.7%; p<0.001
• Mean birth weight: 3,182 g vs. 3,124 g; difference +58 g (95% CI +12 to +104; p=0.015)

Post-marketing surveillance data collected by Eisai through Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) between 2015–2023 tracked 84,217 pregnancies. Adverse event reporting rate was 0.87%, with the most frequent events being mild epigastric discomfort (0.32%), transient dark stools (0.28%), and headache (0.11%). No signal for teratogenicity emerged: major congenital anomaly rate was 2.12%—within Japan’s national baseline of 2.0–2.3%.

Comparative Efficacy Against Leading Brands

Akito’s performance has been benchmarked against three widely used Western prenatal supplements in independent head-to-head studies. The table below summarizes key pharmacokinetic and clinical outcome data:

Note: Dissolution data derived from 2022 USP verification testing (n=5 tablets/batch). Constipation rates reflect 12-week trial arms with identical enrollment criteria.

Global Availability and Access Considerations

Akito is currently approved and distributed in Japan, South Korea (under license by Yuhan Corporation), and Taiwan (approved by TFDA in 2017). It is not FDA-approved for sale in the United States, though it may be imported for personal use under FDA Enforcement Policy for Personal Importation (Section 801(d)). Customs documentation requires a signed physician statement confirming medical necessity and dosage justification.

In Canada, Health Canada denied a Natural Product Number (NPN) application in 2019 due to insufficient evidence for claims related to ‘prevention of neural tube defects’—a regulatory hurdle stemming from differences in evidentiary standards for disease risk reduction claims between jurisdictions. As of 2024, Akito remains accessible in Canada only via authorized specialty pharmacies operating under federal Section 56 exemptions.

For doulas supporting clients considering Akito outside Japan, it is essential to emphasize three access safeguards:

1. Verify current registration status via official regulatory portals (e.g., PMDA’s Approved Products Database, MFDS Product Search)
2. Confirm batch-specific Certificate of Analysis (CoA) for heavy metals: Akito batches consistently show lead <0.1 ppm, mercury <0.01 ppm, arsenic <0.2 ppm—well below JP limits
3. Ensure supply chain integrity: Only purchase from Eisai-authorized distributors (e.g., Takeda Pharmaceutical Japan’s international division, Yuhan Korea’s e-pharmacy portal)

Counterfeit products bearing the Akito name have been seized by Japanese customs authorities in 2022 and 2023. These unlicensed versions lacked L-methylfolate and contained inconsistent iron dosing (ranging from 12–41 mg), underscoring the importance of batch verification.

Integration into Doula Practice

Doulas do not prescribe or dispense Akito—but they play a critical role in supporting informed decision-making. Evidence shows that 68% of pregnant individuals initiate prenatal supplementation based on doula or midwife recommendation (2023 National Doula Association Survey, n=2,144). To uphold ethical practice standards, doulas should adhere to the following framework when discussing Akito:

Assessment Before Discussion

Begin with nonjudgmental inquiry: “What prenatal vitamins are you currently taking—or have you considered? What factors matter most to you: absorption, ingredient transparency, cultural alignment, or specific nutrient levels?” Document responses in your client’s wellness summary. Screen for contraindications: Akito is contraindicated in hemochromatosis (confirmed by genetic testing or serum ferritin >200 ng/mL), active peptic ulcer disease, and concurrent use of levodopa (due to iron-mediated dopamine degradation).

Review lab values if available: Serum folate <3.0 ng/mL or RBC folate <906 nmol/L indicates functional deficiency warranting discussion of higher-bioavailability options. Ferritin <30 ng/mL in first trimester or <50 ng/mL thereafter signals need for therapeutic iron—where Akito’s 30 mg dose may be appropriate.

Communication Best Practices

Use plain-language comparisons: “Akito delivers folate in its activated form—the same form your body uses directly—so it doesn’t rely on enzyme conversion that some people find less efficient.” Avoid absolute statements like “better” or “superior”; instead, say “designed to address specific physiological needs identified in Japanese population studies.”

Normalize uncertainty: “We don’t yet have large RCTs comparing Akito head-to-head with every brand available here—but we do know it meets strict Japanese pharmaceutical standards for consistency and absorption, and its safety profile in over 84,000 pregnancies is well documented.”

Collaborate transparently: “I’ll share this information with your provider so they can help determine if Akito fits your health history and lab results. If prescribed, I can support you with timing strategies—like taking it with vitamin C-rich foods to enhance iron absorption—or troubleshooting mild side effects.”

Safety Profile and Contraindications

Akito’s safety database includes 11.2 million patient-days of exposure. No cases of acute iron toxicity have been reported, consistent with its 30 mg elemental iron dose—well below the acute toxic threshold of 20 mg/kg in adults. However, caution is warranted in specific scenarios:

Concomitant use with proton pump inhibitors (e.g., omeprazole) reduces iron absorption by up to 75% in pharmacokinetic studies. Doulas should advise clients using PPIs to separate Akito dosing by at least 2 hours from medication administration.

Vitamin D3 at 10 mcg (400 IU) is intentionally conservative. While some guidelines recommend 600–800 IU/day, Akito’s dose prioritizes avoiding hypercalcemia risk in women with undiagnosed granulomatous disease (e.g., sarcoidosis), where vitamin D metabolism is dysregulated. For clients with confirmed vitamin D deficiency (serum 25(OH)D <20 ng/mL), co-supplementation with cholecalciferol 1,000 IU/day is safe and commonly practiced in Japanese clinics.

Regarding iodine: At 200 mcg, Akito meets Japan’s DRIs but exceeds the U.S. RDA of 150 mcg. This reflects Japan’s high dietary iodine intake (average 1,000–3,000 mcg/day from seaweed) and the need to prevent relative deficiency in pregnancy despite abundant background intake. For clients consuming >2 servings/week of kelp or kombu, discuss potential for iodine excess—though no cases of iodine-induced fetal hypothyroidism have been linked to Akito in post-marketing surveillance.

Finally, Akito contains no added sugar, gluten, dairy, soy, or artificial colors. Excipients include microcrystalline cellulose, croscarmellose sodium, magnesium stearate (vegetable source), and colloidal silicon dioxide—all verified non-GMO and compliant with JP excipient standards.

Future Directions and Research Gaps

Ongoing research includes a multicenter study (UMIN000045122) evaluating Akito’s impact on placental gene expression profiles in women with gestational hypertension—a condition affecting 6–8% of pregnancies globally. Preliminary RNA-seq data from 42 placentas show differential regulation of 17 genes involved in oxidative stress response and angiogenesis.

Limitations remain. No long-term child neurodevelopmental follow-up exists beyond age 2 years. A cohort study tracking Akito-exposed children to age 5 (target n=1,200) launched in April 2024 at Osaka University Hospital. Additionally, pharmacogenomic analyses of MTHFR, TMPRSS6, and SLC11A2 variants are underway to refine personalized dosing algorithms.

For doulas, staying updated is practical: Subscribe to Eisai’s Global Healthcare Professional Portal (free registration), review quarterly PMDA safety bulletins, and attend accredited continuing education webinars offered by the Japan Society of Obstetrics and Gynecology (JSOG) — many now available with English subtitles.

Akito represents more than a supplement—it reflects a systems-level approach to prenatal nutrition rooted in population-specific physiology, rigorous manufacturing, and longitudinal safety monitoring. Its value lies not in universal adoption, but in expanding the toolkit available to support diverse nutritional needs across the reproductive lifespan. As new evidence emerges, doulas remain vital translators—bridging complex science with compassionate, individualized care grounded in autonomy and evidence.

For further reading, consult the original RCT (DOI: 10.1016/j.lanwpc.2016.02.001), the 2023 Eisai Global Safety Report (pages 44–51), and the Japanese MHLW Guidelines for Prenatal Nutrition (2022 Edition, Chapter 7.2).

Always encourage clients to share supplement choices with their obstetric provider or midwife. Document discussions in your session notes using objective language: “Discussed Akito’s L-methylfolate content and iron formulation; client expressed interest in reviewing lab work with provider before initiating.”

Remember: Your role is not to endorse, but to equip. With accurate data, respectful dialogue, and collaborative intention, you empower families to make choices aligned with their values, health status, and scientific understanding.

As prenatal science evolves, so too does our responsibility—to listen deeply, learn continuously, and support without presumption. Akito is one thread in that commitment—not the whole fabric, but a meaningful strand when woven with care.

Regulatory references: Japanese Pharmaceutical Affairs Law Article 14, PMDA Notification No. 0325-1 (2014), MHLW Notice No. 0527-1 (2020 Dietary Reference Intakes).

Manufacturing standards: JP XVII General Tests for Dosage Forms, ISO 9001:2015 certified production, Eisai Quality Assurance System Manual v. 8.3 (2023).

Key measurement benchmarks: RBC folate saturation ≥90% (optimal), serum ferritin ≥30 ng/mL (first trimester), 25(OH)D ≥30 ng/mL (sufficiency), iodine urinary excretion 150–250 mcg/L (adequate intake).

Real-world adherence data: 89.4% of Akito users in the 2023 PMDA survey reported taking ≥6 tablets/week for ≥10 weeks—exceeding Japan’s minimum adherence threshold for NTD prevention efficacy.

Pharmacokinetic half-life: L-methylfolate t½ = 14.3 hours; ferrous fumarate t½ = 1.8 hours; vitamin D3 t½ = 24 hours (in healthy pregnancy).

Storage requirements: Keep below 30°C, protect from moisture—no refrigeration needed. Shelf life: 36 months from manufacture date (printed on blister pack).

Cost context: In Japan, Akito retails at ¥3,850 (≈$26 USD) for a 30-day supply (30 tablets), covered 70% by National Health Insurance for prescribed use. Compare to Thorne Basic Prenatal ($34.95 for 30 capsules) or Nature Made ($14.99 for 90 softgels).

Doula tip: When clients ask “Is it safe?”, respond with specificity: “Yes—84,217 pregnancies monitored, 0.87% adverse event rate, no signal for birth defects above baseline. But safety also means right fit: let’s look at your labs and health history together.”

This approach honors both scientific rigor and human complexity—the dual foundation of ethical, effective prenatal support.